# Combination With Gemcitabine in Advanced Pancreatic Cancer

> **NCT01251640** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 90 (actual)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** BAY86-9766+Gemcitabine

## Key facts

- **NCT ID:** NCT01251640
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-01
- **Primary completion:** 2013-02-11
- **Final completion:** 2013-08-01
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251640, "Combination With Gemcitabine in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01251640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*